Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
DDDr. Dereck Mush, MD, MBA
Jun 5
Generate Biomedicines
Applies generative machine learning to invent novel proteins and therapeutics based on biological principles.
What they do
The company uses generative artificial intelligence models to predict protein structures and design custom therapeutics. Biotech and pharmaceutical companies utilize its platform to engineer novel enzymes, antibodies, and proteins to address previously untreatable medical conditions.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Somerville, United States
- Region
- North America
- Founded
- 2018
- Total funding
- $740M raised
Notable investors: Flagship Pioneering, Fidelity Management, T. Rowe Price, ARCH Venture Partners.
Also in Biotech & Pharma
Related on The Signal
The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
AI is moving upstream, from molecule design into disease target identification itself
DDDr. Dereck Mush, MD, MBA
Mar 18
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
DDDr. Dereck Mush, MD, MBA
Sep 23